[1]刘海新,毕迎惠,郭成业,等.长春瑞滨并顺铂治疗晚期NSCLC病人骨髓抑制发生时间与近期疗效相关性[J].齐鲁医学杂志,2017,32(03):279-280,284.[doi:10.13362/j.qlyx.201703009]
 LIU Haixin,BI Yinghui,GUO Chengye,et al.ASSOCIATION BETWEEN TIME OF ONSET OF MYELOSUPPRESSION AND SHORT-TERM RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH VINORELBINE AND CISPLATIN[J].Medical Journal of Qilu,2017,32(03):279-280,284.[doi:10.13362/j.qlyx.201703009]
点击复制

长春瑞滨并顺铂治疗晚期NSCLC病人骨髓抑制发生时间与近期疗效相关性()
分享到:

《齐鲁医学杂志》[ISSN:1008-0341/CN:37-1280/R]

卷:
第32卷
期数:
2017年03期
页码:
279-280,284
栏目:
出版日期:
2017-08-07

文章信息/Info

Title:
ASSOCIATION BETWEEN TIME OF ONSET OF MYELOSUPPRESSION AND SHORT-TERM RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH VINORELBINE AND CISPLATIN
文章编号:
1008-0341(2017)03-0279-03
作者:
刘海新1毕迎惠1郭成业1张亚琨2
青岛市市立医院(集团),山东 青岛 266011 1 西院区肿瘤一科; 2 东院区肿瘤科
Author(s):
LIU Haixin BI Yinghui GUO Chengye ZHANG Yakun
Department of Oncology, The Qingdao Municipal Hospital (Group), Qingdao 266011, China
关键词:
非小细胞肺药物疗法骨髓抑制治疗结果
Keywords:
carcinoma non-small-cell lung drug therapy hematological toxicity treatment outcome
分类号:
R730.26
DOI:
10.13362/j.qlyx.201703009
文献标志码:
A
摘要:
目的 探讨接受长春瑞滨并顺铂方案(NP方案)一线化疗的晚期非小细胞肺癌(NSCLC)病人骨髓抑制发生时间与近期疗效的关系。
方法 共收集晚期NSCLC病人138例,均接受至少2周期NP方案一线化疗,按骨髓抑制发生时间分为早期骨髓抑制组(第1~2周期化疗期间发生骨髓抑制)和非早期骨髓抑制组(第3~6周期化疗期间发生骨髓抑制或化疗期间无骨髓抑制),分析其与近期化疗效果的关系。
结果 早期骨髓抑制组、非早期骨髓抑制组治疗客观有效率分别为71.8%(69/96)、35.7%,两组比较差异有显著性(χ2=16.04,P<0.05);两组肿瘤控制率分别为81.3%、64.3%,两组比较差异无显著性(P>0.05)。
结论 对于接受NP方案一线化疗的晚期NSCLC病人,早期发生骨髓抑制是影响近期化疗效果的有利因素,对化疗效果具有一定的预测价值。
Abstract:

Objective  To investigate the association between time of onset of myelosuppression and short-term response in patients with advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and cisplatin (NP regimen). Methods  A total of 138 patients with advanced NSCLC who received at least two cycles of first-line chemotherapy with NP regimen were enrolled, and according to the time of onset of myelosuppression, these patients were divided into early myelosuppression group (myelosuppression occurred during the 1-2 cycles of chemotherapy) and non-early myelosuppression group (myelosuppression occurred during the 3-6 cycles of chemotherapy or no myelosuppression occurred during chemotherapy). The association between time of onset of myelosuppression and short-term response was analyzed.
Results  The objective response rate was 71.8% (69/96) in the early myelosuppression group and 35.7% in the non-early myelosuppression group, and there was a significant difference between the two groups (χ2=16.04,P<0.05). There was no significant difference in tumor control rate between the two groups (81.3% vs 64.3%,P>0.05).
Conclusion  In patients with advanced NSCLC who receive the first-line chemotherapy with NP regimen, early onset of myelosuppression is a favorable factor for short-term response to chemotherapy and has a certain value in predicting the efficacy of chemotherapy.



更新日期/Last Update: 2017-08-12